ArticleNature biomedical engineering2026
Accelerating primer design for amplicon sequencing using large language model-powered agents.
Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeted sequence capture of coxsackievirus A6 using nanopore sequencing directly from clinical specimens.Microbiology spectrum · 2026Article
- Research progress on nucleic acid amplification-based detection technologies for phytopathogenic fungi.Applied microbiology and biotechnology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pre-trained knowledge compressed in large language models is addressing diverse scientific challenges and catalysing the progression of autonomous laboratory systems, synergized with liquid handling robots. Here we introduce PrimeGen, an orchestrated multi-agent system powered by large language models, designed to streamline labour-intensive primer design tasks for targeted next-generation sequencing. PrimeGen uses GPT-4o as a central controller to engage with experimentalists for task planning and decomposition, coordinating various specialized agents to execute distinct subtasks. These include an interactive search agent for retrieving gene targets from databases, a primer agent for designing primer sequences across multiple scenarios, a protocol agent for generating executable robot scripts through retrieval-augmented generation and prompt engineering, and an experiment agent equipped with a vision language model for detecting and reporting anomalies. We experimentally demonstrate the effectiveness of PrimeGen across a variety of applications. PrimeGen can accommodate up to 955 amplicons, ensuring high amplification uniformity and minimizing dimer formation. Our development underscores the potential of collaborative agents, coordinated by generalist foundation models, as intelligent tools for advancing biomedical research.
Indexed as
Identifiers
40738975What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.